Date: 2016-03-17
Type of information: Licensing agreement
Compound: integrin antagonists
Company: Galapagos (Belgium) Thrombogenics (Belgium)
Therapeutic area: Ophtalmological diseases
Type agreement: licensing
Action mechanism: integrin antagonist
Disease: diabetic eye disease
Details: * On March 17 2016, ThromboGenics, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, announces that it has signed a global and exclusive license agreement with Galapagos to develop and commercialize integrin antagonists for the treatment of diabetic eye disease. The license agreement will give ThromboGenics access to a collection of integrin antagonists developed by Galapagos. Research to-date suggests that integrin antagonists could play an important role in the treatment of back of the eye diseases, including diabetic eye diseases. Initially, ThromboGenics intends to further explore and characterize the integrin antagonists that it has in-licensed from Galapagos using a number of well validated preclinical models of diabetic eye disease. ThromboGenics believes that by gaining access to these molecules, it has the potential to develop a novel small molecule integrin antagonist which could be used to treat a broad range of patients with diabetic retinopathy, with or without diabetic macular edema. ThromboGenics has designated the most advanced of these integrin antagonist drug candidates as THR-687.
Financial terms: Under the terms of the agreement, ThromboGenics will pay a €1 million upfront technology-transfer payment to Galapagos. Galapagos will also be entitled to receive certain development and commercial milestone payments plus royalties based on any future annual net sales of products that originated from its library of integrin antagonists.
Latest news:
